WO2010096551A3 - Antimicrobial compositions - Google Patents

Antimicrobial compositions Download PDF

Info

Publication number
WO2010096551A3
WO2010096551A3 PCT/US2010/024576 US2010024576W WO2010096551A3 WO 2010096551 A3 WO2010096551 A3 WO 2010096551A3 US 2010024576 W US2010024576 W US 2010024576W WO 2010096551 A3 WO2010096551 A3 WO 2010096551A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
antimicrobial compositions
crystallization inhibitor
basifϊer
basifer
Prior art date
Application number
PCT/US2010/024576
Other languages
French (fr)
Other versions
WO2010096551A2 (en
Inventor
Danping Li
Eric S. Burak
David S. Dresback
Original Assignee
Rib-X Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rib-X Pharmaceuticals, Inc. filed Critical Rib-X Pharmaceuticals, Inc.
Publication of WO2010096551A2 publication Critical patent/WO2010096551A2/en
Publication of WO2010096551A3 publication Critical patent/WO2010096551A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising a quinolone carboxylic acid compound and an absorption enhancer. In further embodiments, the compositions further comprise a basifer or a crystallization inhibitor, or both a basifϊer and a crystallization inhibitor. These compositions are useful for treating, preventing, or reducing the risk of infection.
PCT/US2010/024576 2009-02-18 2010-02-18 Antimicrobial compositions WO2010096551A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15346309P 2009-02-18 2009-02-18
US61/153,463 2009-02-18
US25147509P 2009-10-14 2009-10-14
US61/251,475 2009-10-14

Publications (2)

Publication Number Publication Date
WO2010096551A2 WO2010096551A2 (en) 2010-08-26
WO2010096551A3 true WO2010096551A3 (en) 2010-12-16

Family

ID=42634437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/024576 WO2010096551A2 (en) 2009-02-18 2010-02-18 Antimicrobial compositions

Country Status (1)

Country Link
WO (1) WO2010096551A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015011760A (en) 2013-03-15 2016-06-10 Melinta Therapeutics Inc Methods of treating infections in overweight and obese patients using antibiotics.
TW201444558A (en) * 2013-03-15 2014-12-01 Melinta Therapeutics Inc Methods of treating gonorrhea infections using quinolone antibiotics
CN103788366B (en) * 2014-01-22 2015-10-28 沈阳药科大学 Mono methoxy polyethylene glycol-two sulphur-two VE-succinate and Synthesis and applications thereof
TW201605447A (en) * 2014-06-20 2016-02-16 美林塔治療學有限公司 Methods for treating infections
TWI732337B (en) * 2014-06-20 2021-07-01 美商梅琳塔有限責任公司 Pharmaceutical composition and use thereof
CN105693695A (en) * 2014-11-24 2016-06-22 重庆医药工业研究院有限责任公司 Delafloxacin meglumine salt crystal form, and preparation method thereof
CN107789324B (en) * 2016-08-31 2021-05-25 鲁南制药集团股份有限公司 Delaxacin meglumine for injection and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0549857A1 (en) * 1991-12-31 1993-07-07 Korea Research Institute Of Chemical Technology Antibacterial quinolone carboxylic acid derivatives
US20020182255A1 (en) * 1999-03-31 2002-12-05 Samir Roy Quinolone carboxylic acid compositions and related methods of treatment
US20030032600A1 (en) * 2001-03-05 2003-02-13 Ulrich Stephen A. Taste masked liquid pharmaceutical compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0549857A1 (en) * 1991-12-31 1993-07-07 Korea Research Institute Of Chemical Technology Antibacterial quinolone carboxylic acid derivatives
US20020182255A1 (en) * 1999-03-31 2002-12-05 Samir Roy Quinolone carboxylic acid compositions and related methods of treatment
US20030032600A1 (en) * 2001-03-05 2003-02-13 Ulrich Stephen A. Taste masked liquid pharmaceutical compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLLNOT EM ET AL.: "Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers.", J. CONTROL. RELEASE., vol. 111, no. 1-2, 10 January 2006 (2006-01-10), pages 35 - 40 *
KHOUGAZ K ET AL.: "Clas SD. Crystallization inhibition in solid dispersions of MK-05 91 and poly(vinylpyrrolidone) polymers.", J. PHARM. SCI., vol. 89, no. 10, October 2000 (2000-10-01), pages 1325 - 1334 *
TOMIOKA H ET AL.: "Comparative antimicrobial activities of the newly synthes ized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.", ANTIMICROB. AGENTS CHEMOTHER., vol. 44, no. 2, February 2000 (2000-02-01), pages 283 - 286 *

Also Published As

Publication number Publication date
WO2010096551A2 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
WO2010096551A3 (en) Antimicrobial compositions
WO2010056872A3 (en) Antimicrobial compositions
WO2008051416A3 (en) Compounds that inhibit the activity of hsp90 for treating infections
WO2011047319A3 (en) Antimicrobial compounds and methods of making and using the same
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2011047323A3 (en) Antimicrobial compounds and methods of making and using the same
WO2010057101A3 (en) Compounds useful as hiv blockers
WO2012021796A8 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
EP2330894B8 (en) Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
WO2009147075A3 (en) Pharmaceutical compositions containing a crystalline form of posaconazole
MX2010014041A (en) A crystalline form of posaconazole.
WO2010108187A3 (en) Compounds and methods for treating mammalian gastrointestinal microbial infections
MY162636A (en) Anti parisitic dihydroazole compounds and compositions comprising same
WO2008061724A3 (en) Compositions comprising carnosic acid 12-methylether
WO2010029302A3 (en) Compounds for treating viral infections
NZ596628A (en) Ketolide compounds having antimicrobial activity
WO2008086122A3 (en) Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
WO2012015986A3 (en) Substituted dioxopiperidinyl phthalimide derivatives
WO2011054741A3 (en) Crystalline complexes of 4-hydroxy benzoic acid and selected pesticides
WO2010031832A3 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
WO2011047320A3 (en) Antimicrobial compounds and methods of making and using the same
WO2010039654A3 (en) Topical treatment of skin infection
WO2007110834A3 (en) Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
WO2011088160A3 (en) Novel cyp17 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10744292

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 10744292

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE